Top trio strengthen Mogrify Scientific Advisory Board
Transformative cell conversion company Mogrify has expanded its Scientific Advisory Board with the appointments of three new members.
Professors Christine Mummery, Graziella Pellegrini and Giulio Cossu will apply their experience in the transition of stem cell approaches from proof-of-concept through the clinic to product approval, to support the Cambridge company in developing scalable off-the-shelf therapies for diseases with a high unmet clinical need.
Mogfrify’s vision is to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies.
Christine Mummery is a Professor of Developmental Biology in the Department of Anatomy and Embryology at Leiden University Medical Center and founded the first induced pluripotent stem cell core facility in the Netherlands.
Professor Mummery became a guest professor at the Technical University of Twente to develop organ-on-chip models based on stem cells, is founding chair of the European Organ-on-Chip Society and heads a multimillion-euro research program focused on implementing these models in human stem cell research.
She is a member of the Royal Netherlands Academy of Science, past board member of the Netherlands Medical Research Council and holds European Research Council Grants to study cardiac development and disease in humans based on stem cell models.
Graziella Pellegrini is a Professor at the University of Modena and Reggio Emilia, Cell Therapy Program Coordinator at the Centre for Regenerative Medicine “Stefano Ferrari”, and co-founder and R & D director at Holostem Terapie Avanzate S.r.l.
Professor Pellegrini is renowned for her work in translational medicine and has developed epithelial stem cell-mediated cell and gene therapies for the treatment of severe eye and skin disease, including Holoclar®, the first stem cell-based medicinal product to be approved by the European Commission.
Giulio Cossu, MD is a Professor of Regenerative Medicine at The University of Manchester and visiting professor at the Max Delbruck Centre, Charitè in Berlin.
He is a fellow of the Medical Academy, Accademia dei Lincei, and European Academy of Science. He has been Panel Chair at the European Research Council and a member of the Committee for Advanced Therapies at the European Medicines Agency.
Professor Cossu is recognised for his pioneering work on skeletal myogenesis, the identification and characterisation of mesoangioblasts, and the first cell therapy trial to utilise stem cells for muscular dystrophy. He has authored over 250 peer-reviewed publications and secured research grants for over €20 million.
Darrin Disley, CEO at Mogrify, said: “Profs. Mummery, Pellegrini and Cossu bring a breadth of experience in stem cell approaches and cell therapy to the Mogrify SAB.
“Their know-how and expertise alongside that of existing SAB members will be vital in driving the application of our direct cell conversion technologies to develop novel cell and gene therapies capable of progressing through clinical development and onto regulatory approval.”